The Eplontersen Pregnancy and Lactation Outcomes Study

NCT07205666

Status RECRUITING
Sponsor AstraZeneca
Enrollment 10 participants

Key Eligibility Criteria

Inclusion (2)

- all pregnancy and/or lactation cases with exposure to eplontersen and a diagnosis of an approved indication for treatment with eplontersen
- all adverse event reports in infants in the first 12 months of age that are or can be linked to pregnancy or lactation reports in individuals previously diagnosed with an approved indication and exposed to eplontersen during pregnancy or lactaction

Exclusion (1)

- all case reports considered invalid (i.e. minimum data is not provided at first report nor follow-up), or where reporter indicates that they do not wish to be contacted to obtain follow-up information, or the reporter/patient cannot be identified

Locations (1 total)

Research Site, Frankfurt, Germany